HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

tegobuvir

a non-structural protein 5B polymerase inhibitor

Also Known As:

5-((6-(2,4-bis(trifluoromethyl)phenyl)pyridazin-3-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo(4,5-c)pyridine; GS-333126; GS-9190

Networked: 9 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridazines: 11
    - tegobuvir: 9
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - tegobuvir: 9

Experts

1.	McHutchison, John G: 2 articles (07/2014 - 03/2012)
2.	Mo, Hongmei: 2 articles (07/2014 - 03/2012)
3.	Hajiagha Bozorgi, Atefeh: 1 article (01/2022)
4.	Kobarfard, Farzad: 1 article (01/2022)
5.	Mosayebnia, Mona: 1 article (01/2022)
6.	Rezaeianpour, Maliheh: 1 article (01/2022)
7.	Banik, Bimal K: 1 article (01/2021)
8.	Borah, Preetismita: 1 article (01/2021)
9.	Mahapatra, Manoj Kumar: 1 article (01/2021)
10.	Ravi Kumar, B V V: 1 article (01/2021)

Related Diseases

1.	Infections 01/01/2016 - "GS-9190 is a NS5B non-nucleoside analogue with demonstrated effectiveness in a Phase 1 monotherapy study and in combination with other DAAs for treatment of chronic HCV infection. " 01/01/2012 - "Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in patients with genotype 1 chronic HCV infection. " 07/01/2014 - "All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection."
2.	Chronic Hepatitis C 07/01/2014 - "This phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VDV), non-nucleoside NS5B inhibitor tegobuvir (TGV), and ribavirin (RBV) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 1 without cirrhosis. "
3.	Fibrosis (Cirrhosis) 07/01/2014 - "This phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VDV), non-nucleoside NS5B inhibitor tegobuvir (TGV), and ribavirin (RBV) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 1 without cirrhosis. "
4.	COVID-19 01/01/2022 - "Re-tasking or taking inspiration from the structures of tegobuvir and tipranavir can be a proper approach toward coping with the COVID-19 in the shortest possible time and at the lowest cost.Communicated" 01/01/2023 - "Then, we suggested the cHubGs-guided top-ranked 10 candidate drug molecules (Tegobuvir, Nilotinib, Digoxin, Proscillaridin, Simeprevir, Sorafenib, Torin 2, Rapamycin, Vancomycin and Hesperidin) for the treatment against SARS-CoV-2 infections with IFP diseases as comorbidity. " 01/01/2021 - "This review focuses on drug repurposing strategy applied for existing drugs including Remdesivir, Favipiravir, Ribavirin, Baraticinib, Tocilizumab, Chloroquine, Hydroxychloroquine, Prulifloxacin, Carfilzomib, Bictegravir, Nelfinavir, Tegobuvir and Glucocorticoids etc to determine their effectiveness toward the treatment of COVID-19."
5.	Hepatitis C 03/01/2012 - "The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C." 06/15/2014 - "The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addition to those that are already developed [telaprevir (Incivek®) and boceprevir (Victrelis®)], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 December 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055. "

Related Drugs and Biologics

1.	Nucleosides
2.	Ribavirin (Virazole)
3.	Proteins (Proteins, Gene)
4.	Protease Inhibitors (Protease Inhibitor)
5.	ledipasvir
6.	GS-9451
7.	Antiviral Agents (Antivirals)
8.	Simeprevir
9.	GS-9256
10.	deleobuvir